WakeMed Cancer Care - Waverly Hematology & Medical Oncology

Clinical research site in Cary, North Carolina

As of July 2026, 2 paid clinical trials are recruiting at WakeMed Cancer Care - Waverly Hematology & Medical Oncology in Cary, North Carolina. Active studies at this site cover conditions such as Breast Neoplasms, Neoplasm Metastasis and Hematologic Malignancies. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at WakeMed Cancer Care - Waverly Hematology & Medical Oncology (2)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

43 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting·Listed Apr 2018

Apply to this trial

Explore more

Paid clinical trials in Cary, NC · North Carolina clinical trials

WakeMed Cancer Care - Waverly Hematology & Medical Oncology

Recruiting clinical trials at WakeMed Cancer Care - Waverly Hematology & Medical Oncology (2)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

More research sites in Cary

Explore more